Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
← catalyst calendarSponsored by Syndax Pharmaceuticals (industry) · SNDX — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
41actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-04 | actual | When the study began enrolling |
| Primary completion | 2025-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-16 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-06 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer
- Solid Tumors
Interventions
- Drug: Revumenib — also filed as SNDX-5613
- Drug: Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
measured Day 1 up to Day 28
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
measured Up to 2.2 years
Phase 1: Disease Control Rate (DCR)
measured Up to 2.2 years
Phase 1: Overall Response Rate (ORR)
measured Up to 2.2 years
Phase 2: Progression Free Survival (PFS)
measured Up to 2.2 years
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-06-18 · 1.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-21 · 1.8 MB · SAP_001.pdf
Permalink · SNDX's whole pipeline · Catalyst calendar · Every registered study · What changed